Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15

The Jumonji C domain-containing family of histone lysine demethylases (Jumonji KDMs) have emerged as promising cancer therapy targets. These enzymes remove methyl groups from various histone lysines and, in turn, regulate processes including chromatin compaction, gene transcription, and DNA repair....

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Lei, Perez, Ricardo E., Calhoun, Sarah, Maki, Carl G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812751/
https://www.ncbi.nlm.nih.gov/pubmed/35100078
http://dx.doi.org/10.1080/15384047.2021.2020060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812751/
https://www.ncbi.nlm.nih.gov/pubmed/35100078
http://dx.doi.org/10.1080/15384047.2021.2020060

Ejemplares similares